If you attended our International Symposium on Malignant Mesothelioma in March of this year, you may recall the buzz of excitement that coursed throughout the scientific sessions. This buzz sparked excitement throughout the entire mesothelioma community, as we discussed advances in science, the needs of those affected by this disease, and the work being done […]
During the July 2014 board meeting of the Mesothelioma Applied Research Foundation, mesothelioma expert and executive director of the Meso Foundation, Mary Hesdorffer, APRN, stated that mesothelioma patients today have more promising clinical trials to choose from than ever before.
In her talk, she mentioned several trials that have been reporting increased survival and response rates. Some include […]
On July 10, during the research and development portion of the Verastem, Inc.’s investor meeting, Mary Hesdorffer, APRN, the executive director of the Mesothelioma Applied Research Foundation, was a featured speaker. In her talk, Ms. Hesdorffer focused on the need for clinical trials to increase the number of viable therapeutic options for mesothelioma.
According to their website, […]
Contact Verastem, Inc.
Brian Sullivan, 617-252-9314
CAMBRIDGE, MA – Sep. 10, 2013 – Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib). COMMAND is a registration-directed trial of lead cancer stem cell inhibitor […]
Recently, we had the honor to interview Melissa Culligan, RN, BSN, MS, a thoracic surgery nurse with specialized experience designing clinical trials. To listen press PLAY in the above podcast box (it may take a minute for the podcast to load).
In a cancer like mesothelioma, for which there is only one FDA-approved treatment, clinical trials […]